These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 32308402)

  • 1. Hypophosphatemia Associated with Intravenous Iron Therapies for Iron Deficiency Anemia: A Systematic Literature Review.
    Glaspy JA; Lim-Watson MZ; Libre MA; Karkare SS; Hadker N; Bajic-Lucas A; Strauss WE; Dahl NV
    Ther Clin Risk Manag; 2020; 16():245-259. PubMed ID: 32308402
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intravenous Iron-Induced Hypophosphatemia: An Emerging Syndrome.
    Glaspy JA; Wolf M; Strauss WE
    Adv Ther; 2021 Jul; 38(7):3531-3549. PubMed ID: 34053011
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk Factors for and Effects of Persistent and Severe Hypophosphatemia Following Ferric Carboxymaltose.
    Schaefer B; Zoller H; Wolf M
    J Clin Endocrinol Metab; 2022 Mar; 107(4):1009-1019. PubMed ID: 34850000
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interventions for treating iron deficiency anaemia in inflammatory bowel disease.
    Gordon M; Sinopoulou V; Iheozor-Ejiofor Z; Iqbal T; Allen P; Hoque S; Engineer J; Akobeng AK
    Cochrane Database Syst Rev; 2021 Jan; 1(1):CD013529. PubMed ID: 33471939
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Osteomalacia as a Complication of Intravenous Iron Infusion: A Systematic Review of Case Reports.
    Vilaca T; Velmurugan N; Smith C; Abrahamsen B; Eastell R
    J Bone Miner Res; 2022 Jun; 37(6):1188-1199. PubMed ID: 35426179
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intravenous iron administration and hypophosphatemia in clinical practice.
    Hardy S; Vandemergel X
    Int J Rheumatol; 2015; 2015():468675. PubMed ID: 26000018
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ferric carboxymaltose treatment for iron deficiency anemia in children with inflammatory bowel disease: Efficacy and risk of hypophosphatemia.
    Cococcioni L; Pensabene L; El-Khouly S; Chadokufa S; McCartney S; Saliakellis E; Kiparissi F; Borrelli O
    Dig Liver Dis; 2021 Jul; 53(7):830-834. PubMed ID: 33775573
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized trial of intravenous iron-induced hypophosphatemia.
    Wolf M; Chertow GM; Macdougall IC; Kaper R; Krop J; Strauss W
    JCI Insight; 2018 Dec; 3(23):. PubMed ID: 30518682
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hypophosphatemia after high-dose iron repletion with ferric carboxymaltose and ferric derisomaltose-the randomized controlled HOMe aFers study.
    Emrich IE; Lizzi F; Siegel JD; Seiler-Mussler S; Ukena C; Kaddu-Mulindwa D; D'Amelio R; Wagenpfeil S; Brandenburg VM; Böhm M; Fliser D; Heine GH
    BMC Med; 2020 Jul; 18(1):178. PubMed ID: 32654663
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Hypophosphatemia after injectable iron treatments in adults: Comparison between ferric carboxymaltose and iron sucrose].
    Grino M; Rigaux M; Lagarde AV; Robert V; Papailhau C; Vincentelli MB
    Ann Pharm Fr; 2023 Sep; 81(5):790-800. PubMed ID: 36963655
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High Risk of Hypophosphatemia in Patients with Previous Bariatric Surgery Receiving Ferric Carboxymaltose: A Prospective Cohort Study.
    Schoeb M; Räss A; Frei N; Aczél S; Brändle M; Bilz S
    Obes Surg; 2020 Jul; 30(7):2659-2666. PubMed ID: 32221822
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Hypophosphatemia following the administration of intravenous iron formulations: A case report and literature review].
    Lecoq AL; Dong C; Carbonnel F; Becquemont L
    Therapie; 2021; 76(6):705-714. PubMed ID: 33962799
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of Iron Isomaltoside vs Ferric Carboxymaltose on Hypophosphatemia in Iron-Deficiency Anemia: Two Randomized Clinical Trials.
    Wolf M; Rubin J; Achebe M; Econs MJ; Peacock M; Imel EA; Thomsen LL; Carpenter TO; Weber T; Brandenburg V; Zoller H
    JAMA; 2020 Feb; 323(5):432-443. PubMed ID: 32016310
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Severe osteomalacia with multiple insufficiency fractures secondary to intravenous iron therapy in a patient with Rendu-Osler-Weber syndrome.
    Callejas-Moraga EL; Casado E; Gomez-Nuñez M; Caresia-Aroztegui AP
    Bone Rep; 2020 Dec; 13():100712. PubMed ID: 32923530
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Osteomalacia following intravenous iron suppletion].
    Koks N; Donga E; Appelman-Dijkstra NM
    Ned Tijdschr Geneeskd; 2021 Oct; 165():. PubMed ID: 34854600
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hypophosphataemia risk associated with ferric carboxymaltose in heart failure: A pooled analysis of clinical trials.
    Rosano GM; Kalantar-Zadeh K; Jankowska EA
    ESC Heart Fail; 2023 Apr; 10(2):1294-1304. PubMed ID: 36722321
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative safety of intravenous Ferumoxytol versus Ferric Carboxymaltose for the Treatment of Iron Deficiency Anemia: rationale and study design of a randomized double-blind study with a focus on acute hypersensitivity reactions.
    Adkinson NF; Strauss WE; Bernard K; Kaper RF; Macdougall IC; Krop JS
    J Blood Med; 2017; 8():155-163. PubMed ID: 29033620
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hypophosphatemia after high-dose intravenous iron treatment in patients with inflammatory bowel disease: Mechanisms and possible clinical impact.
    Detlie TE; Lindstrøm JC; Jahnsen ME; Finnes E; Zoller H; Moum B; Jahnsen J
    World J Gastroenterol; 2021 May; 27(17):2039-2053. PubMed ID: 34007138
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Choice of High-Dose Intravenous Iron Preparation Determines Hypophosphatemia Risk.
    Schaefer B; Würtinger P; Finkenstedt A; Braithwaite V; Viveiros A; Effenberger M; Sulzbacher I; Moschen A; Griesmacher A; Tilg H; Vogel W; Zoller H
    PLoS One; 2016; 11(12):e0167146. PubMed ID: 27907058
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and Efficacy of Intravenous Ferric Carboxymaltose (750 mg) in the Treatment of Iron Deficiency Anemia: Two Randomized, Controlled Trials.
    Barish CF; Koch T; Butcher A; Morris D; Bregman DB
    Anemia; 2012; 2012():172104. PubMed ID: 22997572
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.